AxioMx

AxioMx was founded in 2012 and is headquartered in Branford, Connecticut. It is a leader in recombinant antibody technology. Its founders, Chris McLeod and Dr. Michael Weiner, are life science entrepreneurs who have previously led successful ventures in genomics, next-generation sequencing, microfluidics, bioinformatics, and proteomics. AxioMx's unique phage display libraries, library screening, and affinity maturation methodology platform provide the company with its technological foundation. The company offers a full range of custom antibody discovery and development services for the research and diagnostics markets.